Quintiles and Quest unveil their clinical trials joint venture

Quintiles ($Q) and Quest Diagnostics ($DGX) rolled out Q2 Solutions, a $575 million joint venture that pairs the CRO's experience running studies with the latter company's expertise in lab tests. The new entity draws on each company's capacity in biostatistics, including Quest's more than 20 billion processed tests and Quintiles' health information culled from more than 60 million patients. The idea is to apply that sprawling data set to the world of lab testing, turning to Quintiles' Rolodex of the world's biggest drugmakers to create a one-of-a-kind offering. Release

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.